You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Has dysgeusia been reported in patients taking Zepbound® (tirzepatide)?
In 2 pooled clinical trials, 0.4% of patients treated with tirzepatide reported experiencing dysgeusia, while no patients in the placebo group reported dysgeusia.
See important safety information, including boxed warning, in the attached prescribing information.
Dysgeusia
Dysgeusia is a condition that changes a person’s sense of taste, making everything taste sweet, sour, bitter, or metallic.1
In a pool of SURMOUNT-1 and SURMOUNT-2 studies, dysgeusia was reported by 0.4% of tirzepatide-treated patients and no placebo-treated patients.2
Enclosed Prescribing Information
References
1Dysgeusia. Boston Medical Center. Updated April 2020. Accessed November 13, 2024. https://www.bmc.org/patient-care/conditions-we-treat/db/dysgeusia
2Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: November 11, 2024